Consistently, we observed that the amount of ctDNA was low in those cases where a TP53 mutation was detected only in the tumor (when using the percentage of the tumor-specific KRAS mutation in pancreatic juice as a surrogate measure for ctDNA level). Here, KRAS is linked to neoplasm.